Congratulations to the winners of the 6th Annual Global Generics & Biosimilars Awards. Click here to view the winners list.
We also would like to thank everyone who attended the 6th Annual Global Generics & Biosimilars Awards, held on 5th November at the Frankfurt Marriott Hotel in Frankfurt, Germany.
The evening was a celebration of achievements across the generics, biosimilars and value added medicines industries, recognizing and rewarding efforts to make more affordable medicines available to more people everywhere.
We also would like to thank our sponsorts for their contribution:
IQVIA™ is a leading global provider of information, innovative technology solutions and contract research services focused on using data and science to help healthcare clients find better solutions for their patients. Formed through the merger of IMS Health and Quintiles, IQVIA offers a broad range of solutions that harness advances in healthcare information, technology, analytics and human ingenuity to drive healthcare forward.
IQVIA enables companies to rethink approaches to clinical development and commercialization, innovate with confidence as well as accelerate meaningful healthcare outcomes. IQVIA has approximately 55,000 employees in more than 100 countries, all committed to making the potential of Human Data Science a reality. IQVIA’s approach to Human Data Science is powered by the IQVIA CORE™, driving unique actionable insights at the intersection of big data, advanced technology and analytics with extensive industry knowledge. To learn more, visit www.iqvia.com.
Aurobindo’s mission is to become the most valued Pharma partner to the World Pharma fraternity by continuously researching, developing and manufacturing a wide range of pharmaceutical products that comply with the highest regulatory standards.
In addition to being the market leader in Semi-Synthetic Penicillin’s, Aurobindo Pharma has a presence in key therapeutic segments such as neurosciences (CNS), cardiovascular (CVS), anti-retroviral, anti-diabetics, gastroenterology and Anti-biotics.
Through cost effective manufacturing capabilities and a few loyal customers, the company also entered the high margin specialty generic formulations segment. Today Aurobindo Pharma has evolved into a knowledge driven company manufacturing active pharmaceutical ingredients and formulation products. It is R&D focused and has a multi-product portfolio with manufacturing facilities in several countries. A well-integrated pharma company, Aurobindo Pharma features among the top 2 Pharmaceutical companies in India in terms of consolidated revenues. Aurobindo exports to over 150 countries across the globe.
In communities around the world affected by chronic poverty, conflict or disasters, easily treatable diseases can mean chronic pain, poor quality of life or even a death sentence. International Health Partners (IHP) was founded in 2003 with a vision to radically enhance access to medicine to the world’s most vulnerable people. IHP enable targeted donations of medicines from a network of over 60 healthcare companies across Europe, and coordinate the safe and responsible supply of these to disaster hit and vulnerable communities across the world. IHP are the only organisation working to this model in the UK. In the last three years IHP have sent over 8.2 million treatments, with a value of over £34.5 million.
Covering all the links of the chemical–pharmaceutical industry. Insud Pharma is Committed to health care since 1977. Their goal is to improve the health of people worldwide providing accessible, efficient, safe and high-quality pharmacological treatments. From a company trading raw materials for the pharmaceutical industry to offering solutions for immediate application in the entire product life cycle, from development and registration, to production and direct supply to customers. 3 business areas of action and a common base: We continue expanding our efforts and investments in R&D to develop new and better therapeutic solutions; Chemo, Exeltis and mAbxience.
About Piramal Pharma Solutions: Piramal Pharma Solutions is a contract development and manufacturing organization (CDMO), offering end-to-end development and manufacturing solutions across the drug life cycle. We serve our clients through a globally integrated network of facilities in North America, Europe and Asia. This enables us to offer a comprehensive range of services including Drug Discovery Solutions, Process & Pharmaceutical Development services, Clinical Trial Supplies and Commercial supply of APIs and Finished dosage forms. We also offer specialized services like development and manufacture of Highly Potent APIs and Antibody Drug Conjugation. Our capability as an integrated service provider & experience with various technologies enables us to serve Innovator and Generic companies worldwide.
Pharmacloud was established in 2009 by Frances Cloud, who was previously an equity analyst and M&A adviser covering the European generic sector. Pharmacloud’s original focus was on writing research about the generic pharmaceutical industry, but since then it has expanded its activities to encompass commercial due diligence, market mapping, market entry strategies, strategic consultancy and M&A support. Europe remains the primary focus, but Pharmacloud has recently completed a number of projects in the US and is increasingly operating in MENA and other emerging markets. Pharmacloud has been involved in many if not most of the generic M&A transactions that have taken place in Europe over the last five years, mainly assisting PE, and is very active in identifying and diligencing big pharma tail end assets for a variety of trade and financial clients.
Pharmawise is a specialist pharmaceutical consultancy. They give their clients strategic, commercial and scientific advice and support through our international network of industry experts.
With deep expertise in your sector, Pharmawise can help you tackle the most complex and specialised challenges; develop strategic and operational plans; and improve the efficiency of operations.